However, minimal development has been achieved in terms of HCC biomarkers although alpha-fetoprotein (AFP) and proteins induced by vitamin K antagonist-II (PIVKA-II) have been used for diagnosis and predicting clinical outcomes. This evidence concerns the gene AFP and hepatocellular carcinoma.